Get started

BIO

Long #ENLV above 18.50, COVID news#ENLV is in the news last week with regards to Covid-19 treatment. I would be looking at the 18.46 area for a retest, and possible entry if we find support. 100% measured move would take the breakout to 23.81 and ultimately that would be my first target. Id consider this trade still healthy above 15.49 and ultimately any lower than 14.54 i would stop out of a longer term position and consider the 10.72-12.32 for a reentry. Based on trend projection confluence and fib levels, id be looking to sell some shares at the 28.00 level If we happen to see price action above these levels, i would consider targeting 37$ down the road. The top of this trading range would be close to $45, Currently trading at 15.49
NASDAQ:ENLVLong
by TradingNomadic
BKYI Bio Key International huge upside potentialBIO-key, Provider of Multi-Factor Identity and Access Management Solutions, Hosts Q2 Investor Call Friday, Aug 14 at 10am ET. Innovative Credit Card Processor Clearent, LLC Switches to BIO-key’s PortalGuard Identity and Access Management Solution to Secure Customer Access and Deliver Secure Reset Capabilities. Source: yahoo finance The analysts are targeting a 2usd price per share. With a market cap of only 16.5 mil but also a debt of 14.5 mil, BKYI is one of the riskiest bets on the market with a huge potential though. The uprising volume is also a great sign. If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:BKYILong
by TopgOptions
$MLNT Breaks Out Ahead of Upcoming 9 Presentations at ECCMIDVery undervalued stock. 52 Week High was $46.00 52 Week Low was $3.22 Revenue for the 4th quarter of 2018 was $35.5 million, an 739% increase year over year. Total revenue for the year is $96.4 million. Could do 2x-3x from this level. Key data presentations at ECCMID 2019 include: Integrated Symposium Presentations •“Update on acute bacterial skin and skin structure infection: current challenges and new therapeutic agents,” chaired by Javier Garau, M.D., Ph.D. (Saturday, April 13, 1:30 - 3:30 p.m., Hall D) •“Light and shadows in the management of serious MDR G-negative infections,” chaired by Matteo Bassetti, M.D. (Monday, April 15, 4:00 p.m. – 6:00 p.m., Hall F) Oral Presentation •Abstract No. 3623 (Sunday, April 14, 11:00 a.m. - 12:00 p.m. CET, Exhibit Hall L): Development and Validation of a Risk Stratification Score for a Mixed Gram-Negative and Gram-Positive Infections among Patients Hospitalized with Skin and Skin Structure Infections in the U.S., Y. Tabek, BD. Poster Presentations Meropenem/vaborbactam (VABOMERE®) •Abstract No. 8308 (Saturday, April 13, 3:30 - 4:30 p.m. CET, Paper Poster Area): Activity of meropenem-vaborbactam and single-agent comparators against KPC-producing Enterobacterales isolates from European countries (2016-2018) stratified by infection type, M. Castanheira, JMI Laboratories •Abstract No. 2825 (Monday, April 15, 12:30 - 1:30 p.m. CET, Paper Poster Area): Multicenter Evaluation of Meropenem/Vaborbactam MIC Results for Enterobacteriaceae and Pseudomonas aeruginosa Using MicroScan Dried Gram-Negative MIC Panels, A. Harrington, Loyola University •Abstract No. 4780 (Monday, April 15, 12:30 - 1:30 p.m. CET, Paper Poster Area): ETEST meropenem/vaborbactam for antimicrobial susceptibility testing of Enterobacterales and Pseudomonas aeruginosa: performance results from a multi-centre study, C. Anglade, bioMérieux, Inc. •Abstract No. 7426 (Tuesday, April 16, 12:30 - 1:30 p.m. CET, Paper Poster Area): An FDA-approved study for an AST disc 510(k) submission: comparison of an oxoid AST disc to a predicate AST disc for meropenem-vaborbactam, N. Hunter, Thermo Fisher Scientific Delafloxacin (BAXDELA®) •Abstract No. 6363 (Monday, April 15, 1:30 - 2:30 p.m. CET, Paper Poster Area): Delafloxacin tentative ECOFF values for common Gram-positive and Gram-negative bacteria, G. Menchinelli, Università Cattolica del Sacro Cuore Oritavancin (ORBACTIV®) •Abstract No. 4151 (Monday, April 15, 1:30 - 2:30 p.m. CET, Paper Poster Area): Oritavancin Activity against Staphylococcus aureus Clinical Isolates Causing Serious Infections in Hospitalized Patients in Europe (2017-2018), C. Carvalhaes, JMI Laboratories marketwirenews.com
MLong
by StockGuild
$CELZ Continues North with Accelerating Accumulation$CELZ is currently on a clear and clean breakout in anticipation of the May 18th- 21st Presentation at the American Urological Association Convention in San Francisco. An 8K was released recently showing that shares were issued at .10 and as high as .30 levels The following link shows that the CEO has been buying on the way up as well: backend.otcmarkets.com Look who covered $OWCP (Which ran from .003 to >> $3.05) and has been covering CELZ since Feb 18, 2018 (PPS @ .0094 at that time) CORRELATION? ;-) ----> t.co Also forgot to mention the debt is almost completely eliminated from the books :-)
CLong
by StockGuild
4